Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified CHOP every 2 weeks plus G-CSF versus standard CHOP every 3 weeks in intermediate-risk non-Hodgkin lymphoma
NL-OMON28643Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Nov 1994
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclophosphamide, doxorubicin, vincristine, prednisone, filgrastim in non-Hodgkin lymphoma (NHL), sponsored by HOVON. Started Nov 1994; status: active, not recruiting.
02
Drugs
cyclophosphamidedoxorubicinvincristineprednisonefilgrastim
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON28643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28643.